Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 1
1971 1
1972 3
1975 4
1976 7
1977 10
1978 3
1979 6
1980 1
1981 8
1982 3
1983 5
1984 5
1985 3
1986 4
1987 9
1988 5
1989 6
1990 4
1991 2
1992 4
1993 1
1994 3
1996 2
1997 2
1998 2
1999 3
2000 3
2001 4
2002 1
2003 1
2004 3
2005 7
2006 5
2007 1
2009 1
2010 1
2011 2
2012 4
2013 2
2014 1
2015 3
2016 2
2017 6
2018 6
2019 8
2020 19
2021 10
2022 14
2023 7
2024 12
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.
Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, Caudwell V, Chiche L, Couzi L, Daniel L, Deligny C, Dussol B, Faguer S, Gobert P, Gondran G, Huart A, Hummel A, Kalbacher E, Karras A, Lambert M, Le Guern V, Lebourg L, Loubière S, Maillard-Lefebvre H, Maurier F, Pha M, Queyrel V, Remy P, Sarrot-Reynauld F, Verhelst D, Hachulla E, Amoura Z, Daugas E; WIN-Lupus study group. Jourde-Chiche N, et al. Ann Rheum Dis. 2022 Oct;81(10):1420-1427. doi: 10.1136/annrheumdis-2022-222435. Epub 2022 Jun 20. Ann Rheum Dis. 2022. PMID: 35725295 Free PMC article. Clinical Trial.
Lupus and vaccinations.
Mathian A, Pha M, Amoura Z. Mathian A, et al. Curr Opin Rheumatol. 2018 Sep;30(5):465-470. doi: 10.1097/BOR.0000000000000525. Curr Opin Rheumatol. 2018. PMID: 29889693 Review.
Leukocyte Proliferation Assay: Version 2.
Potter TM, Cedrone E, Skoczen SL, Neun BW, Dobrovolskaia MA. Potter TM, et al. 2020 May. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. 2020 May. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. PMID: 39013061 Free Books & Documents. Review.
This assay will allow for measurement of a nanoparticles' ability to suppress leukocyte proliferation induced by phytohemaglutinin (PHA-M). This protocol is a modification of part B of the NCL ITA-6.1 (formerly NCL ITA-6)....
This assay will allow for measurement of a nanoparticles' ability to suppress leukocyte proliferation induced by phytohemaglutinin (PHA …
Analysis of Gene Expression Changes in PHA-M Stimulated Lymphocytes - Unraveling PHA Activity as Prerequisite for Dicentric Chromosome Analysis.
Beinke C, Port M, Ullmann R, Gilbertz K, Majewski M, Abend M. Beinke C, et al. Radiat Res. 2018 Jun;189(6):579-596. doi: 10.1667/RR14974.1. Epub 2018 Apr 3. Radiat Res. 2018. PMID: 29613823
Human peripheral whole blood from three healthy donors was separately cultured in RPMI/FCS/antibiotics with BrdU and PHA-M. Diluted whole blood samples were transferred into PAXgene tubes at 0, 12, 24 and 36 h culture time. ...
Human peripheral whole blood from three healthy donors was separately cultured in RPMI/FCS/antibiotics with BrdU and PHA-M. Di …
Leukocyte Proliferation Assay (Immunosuppression): Version 2.1.
Potter TM, Cedrone E, Skoczen SL, Neun BW, Dobrovolskaia MA. Potter TM, et al. 2024 Jul. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. 2024 Jul. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. PMID: 40198039 Free Books & Documents. Review.
This assay will allow for measurement of a nanoparticles' ability to suppress leukocyte proliferation induced by phytohemaglutinin (PHA-M). This protocol is a modification of part B of the NCL ITA-6.1 (formerly NCL ITA-6)....
This assay will allow for measurement of a nanoparticles' ability to suppress leukocyte proliferation induced by phytohemaglutinin (PHA …
Different pathways of human T-cell activation revealed by PHA-P and PHA-M.
O'Flynn K, Russul-Saib M, Ando I, Wallace DL, Beverley PC, Boylston AW, Linch DC. O'Flynn K, et al. Immunology. 1986 Jan;57(1):55-60. Immunology. 1986. PMID: 2417941 Free PMC article.
A combination of monoclonal antibodies to different epitopes of CD2 causes calcium mobilization and mitogenesis. Reagent grade PHA (PHA-M) induces calcium moblization in cells that lack CD2, and its effects in other T cells cannot be blocked by anti-CD2 antibodies. …
A combination of monoclonal antibodies to different epitopes of CD2 causes calcium mobilization and mitogenesis. Reagent grade PHA (PHA …
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases.
Zakine È, Papageorgiou L, Bourguiba R, Mekinian A, Terrier B, Kosmider O, Hirsch P, Jachiet M, Audia S, Ardois S, Adélaïde L, Bigot A, Duriez P, Emile JF, Lazaro E, Fayard D, Galland J, Hié M, Humbert S, Jean A, Kostine M, Lacombe V, Le Guenno G, Lobbes H, Magy-Bertrand N, Marianetti-Guingel P, Mathian A, Outh R, Saillard C, Samson M, Vial G, Bouaziz JD, Moguelet P, Chasset F; National French VEXAS Study Group (NFVS). Zakine È, et al. J Am Acad Dermatol. 2023 Apr;88(4):917-920. doi: 10.1016/j.jaad.2022.10.052. Epub 2022 Nov 5. J Am Acad Dermatol. 2023. PMID: 36343774 No abstract available.
Comparing seven mitogens with PHA-M for improved lymphocyte stimulation in dicentric chromosome analysis for biodosimetry.
Beinke C, Port M, Lamkowski A, Abend M. Beinke C, et al. Radiat Prot Dosimetry. 2016 Feb;168(2):235-41. doi: 10.1093/rpd/ncv286. Epub 2015 May 9. Radiat Prot Dosimetry. 2016. PMID: 25958413 Free PMC article.
Two limiting factors of DCA are the time-consuming lymphocyte stimulation and proliferation using the lectin PHA-M and the upper dose limit of individual dose assessment of 4 Gy. By measuring the mitotic index (MI), the authors investigated systematically whether th …
Two limiting factors of DCA are the time-consuming lymphocyte stimulation and proliferation using the lectin PHA-M and the upp …
Immune cells and inflammatory mediators cause endothelial dysfunction in a vascular microphysiological system.
Rengarajan A, Goldblatt HE, Beebe DJ, Virumbrales-Muñoz M, Boeldt DS. Rengarajan A, et al. Lab Chip. 2024 Mar 12;24(6):1808-1820. doi: 10.1039/d3lc00824j. Lab Chip. 2024. PMID: 38363157 Free PMC article.
HUVECs were co-cultured with PBMCs either directly wherein PBMCs passed through the lumen or indirectly with PBMCs embedded in the supporting collagen hydrogel. We revealed that phytohemagglutinin (PHA)-M activated PBMCs cause endothelial dysfunction in MPS both thr …
HUVECs were co-cultured with PBMCs either directly wherein PBMCs passed through the lumen or indirectly with PBMCs embedded in the supportin …
215 results